Tanvex BioPharma, Inc.

Equities

6541

KYG8676P1037

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 14/05/2024 am IST			5-day change	1st Jan Change
42.2 ^TWD	-3.10%		-5.59%	-35.18%

14/03	Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
06/02	Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	CI

Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023

December 21, 2023 at 05:16 pm IST

Tanvex BioPharma USA, Inc. announced the resignation of Dr. Yun Yen as Chairman/President. Resume of the previous position holder: Tanvex Biopharma, Inc. Chairman/CEO. Effective date is December 29, 2023.

Latest news about Tanvex BioPharma, Inc.

Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer	06/02	CI
Tanvex BioPharma, Inc. Announces the Appointment of Chen, Lin-Cheng as CEO	06/02	CI
Tanvex Biologics Corporation announced that it expects to receive $5 million in funding from Tanvex BioPharma, Inc.	06/02	CI
Tanvex BioPharma USA, Inc. announced that it expects to receive $50 million in funding from Tanvex BioPharma, Inc.	06/02	CI
Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer	05/01	CI
Tanvex BioPharma, Inc. Announces Change of Chairman	29/12	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen Chairperson and Director, Effective December 29, 2023	21/12	CI
Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer	21/12	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as CEO, Effective December 29, 2023	21/12	CI
Tanvex BioPharma, Inc. Announces Resignation of Yun Yen as Chairman/President, Effective December 29, 2023	21/12	CI
Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer	30/11	CI
Tanvex BioPharma, Inc. Appoints Wen Chung Yeh as Chief Financial Officer	13/11	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Tanvex BioPharma, Inc. Announces Management Changes	01/11	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to S&P Global BMI Index	18/23/18	CI
Tanvex BioPharma, Inc.(TWSE:6541) added to Taiwan TAIEX Index	07/23/07	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from Taiwan TAIEX Index	12/23/12	CI
Tanvex BioPharma, Inc.(TWSE:6541) dropped from S&P Global BMI Index	20/23/20	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	08/23/08	CI
Tanvex BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	08/23/08	CI
Tanvex BioPharma, Inc. Appoints Peter K.H. Lin as Agent in Charge of Accounting Officer	03/23/03	CI
Tanvex BioPharma USA, Inc. announced that it expects to receive $55 million in funding from Tanvex BioPharma, Inc.	24/23/24	CI

Chart Tanvex BioPharma, Inc.

Duration

Period

More charts

Company Profile

Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.

Sector

Biotechnology & Medical Research

Calendar

19/06/2024 - Annual General Meeting

More about the company

	1st Jan change	Capi.
TANVEX BIOPHARMA, INC.	-35.18%	22Cr
VERTEX PHARMACEUTICALS INCORPORATED	+3.93%	11TCr
REGENERON PHARMACEUTICALS, INC.	+11.38%	11TCr
BIONTECH SE	-12.84%	2.23TCr
ARGENX SE	-3.70%	2.19TCr
GENMAB A/S	-6.03%	1.86TCr
WUXI APPTEC CO., LTD.	-35.21%	1.81TCr
BEIGENE, LTD.	-10.29%	1.7TCr
NEUROCRINE BIOSCIENCES, INC.	+2.41%	1.37TCr
SAREPTA THERAPEUTICS, INC.	+35.95%	1.24TCr

Bio Therapeutic Drugs